Sulfonamide derivatives
AssigneeEli Lilly and Company
InventorsMacklin Brian Arnold, Paul Leslie Ornstein, Edward C. R. Smith, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
Life of this patent
Estimating the term…
Abstract
The present invention provides certain sulfonamide derivatives useful for potentiating glutamate receptor function in a mammal and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.
Claims11
A compound of the formula:
- wherein
- R1 represents a phenyl, which is unsubstituted or substituted by one or two substituents selected independently from halogen;
- (1-10C)alkyl;
- and a group of formula R14—(La)n—X2—(Lb)m in which X2 represents a bond, La and Lb each represent (1-4C)alkylene, n and m is 0, and R14 represents a phenyl which is unsubstituted or substituted by one or two of halogen, or (1-10C) alkyl,
- R2a and R2b each independently represent hydrogen, or (1-6C)alkyl, and either one of R5, R6, R7 and R8 represents hydrogen, or (1-6C)alkyl, and the remainder of R5, R6, R7 and R8 represent hydrogen;
- or a pharmaceutically acceptable salt thereof;
- with the proviso that if R2a represents hydrogen, then R2b represents (1-6C)alkyl.
A method of potentiating glutamate receptor function in a mammal requiring such treatment, which comprises administering an effective amount of a compound of formula:
- wherein
- R1 represents a phenyl, which is unsubstituted or substituted by one or two substituents selected independently from halogen;
- (1-10C)alkyl;
- and a group of formula R14—(La)n—X2—(Lb)m in which X2 represents a bond, La and Lb each represent (1-4C)alkylene, n and m is 0, and R14 represents a phenyl which is unsubstituted or substituted by one or two of halogen, or (1-10C) alkyl,
- R2a and R2b each independently represent hydrogen, or (1-6C)alkyl, and
- either one of R5, R6, R7 and R8 represents hydrogen, or (1-6C)alkyl, and the remainder of R5, R6, R7 and R8 represent hydrogen;
- or a pharmaceutically acceptable salt thereof.
A method of treating a cognitive disorder;
- a neuro-degenerative disorder;
- age-related dementia;
- age-induced memory impairment;
- movement disorder;
- reversal of a drug-induced state;
- depression;
- attention deficit disorder;
- attention deficit hyperactivity disorder;
- psychosis;
- cognitive deficits associated with psychosis;
- or drug-induced psychosis in a patient, which comprises administering to a patient in need thereof an effective amount of a compound of formula:
- wherein
- R1 represents a phenyl, which is unsubstituted or substituted by one or two substituents selected independently from halogen;
- (1-10C)alkyl;
- and a group of formula R14—(La)n—X2—(Lb)m in which X2 represents a bond, La and Lb each represent (1-4C)alkylene, n and m is 0, and R14 represents a phenyl which is unsubstituted or substituted by one or two of halogen, or (1-10C) alkyl,
- R2a and R2b each independently represent hydrogen, or (1-6C)alkyl, and
- either one of R5, R6, R7 and R8 represents hydrogen, or (1-6C)alkyl, and the remainder of R5, R6, R7 and R8 represent hydrogen;
- or a pharmaceutically acceptable salt thereof.
A method for improving memory or learning ability in a patient, which comprises administering to a patient in need thereof an effective amount of a compound of formula:
- wherein
- R1 represents a phenyl, which is unsubstituted or substituted by one or two substituents selected independently from halogen;
- (1-10C)alkyl;
- and a group of formula R14—(La)n—X2—(Lb)m in which X2 represents a bond, La and Lb each represent (1-4C)alkylene, n and m is 0, and R14 represents a phenyl which is unsubstituted or substituted by one or two of halogen, or (1-10C) alkyl,
- R2a and R2b each independently represent hydrogen, or (1-6C)alkyl, and
- either one of R5, R6, R7 and R8 represents hydrogen, or (1-6C)alkyl, and the remainder of R5, R6, R7 and R8 represent hydrogen;
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.